Does DAA Therapy Up Risk for Liver Cancer? It's Debatable
Eight studies at the 2017 International Liver Congress illuminate the question but the answer is open to interpretation.
Post-Test on Hepatitis C in Primary Care
Take this brief quiz to see what you’ve learned about the challenges and opportunities of HCV management.
Hepatitis C Drugs Meet Resistance Issues
Resistance-associated variants limit the activity of some drugs, but HIV infection treatment may offer some guidance.
Hepatitis C: What If You Do Not Treat?
Severe outcomes may ensue in a high percentage of patients. The authors discuss the consequences in this brief podcast.
Newer Hepatitis C Drugs Mean Direct Action
The “modern era” of treatment features multiple DAAs that target specific steps within the HCV life cycle.
Medicaid Is Tight on Hepatitis C Drug Coverage
State Medicaid programs and private insurance companies have balked at providing these drugs to their insured customers. But the tide is turning.
Hepatitis C Report: What Tests to Order
Testing is recommended for the persons who are more likely to have the virus but not know it.
Hep C Spread in North America: When and How did it Start?
Timing of the rise of hep C in North America is a puzzle. In this Medical News Minute, Dr Bobby Lazzara toplines results of a new study that offer clarity.
Hepatitis C: Pre-treatment Testing and Monitoring At-a-Glance
What are the most important labs to monitor before, during, and after HCV treatment? Essentials in this brief slide show.
By clicking Accept, you agree to become a member of the UBM Medica Community.